Rosuvastatin Treatment Reduces Markers of Monocyte Activation in HIV-Infected Subjects on Antiretroviral Therapy

Eitemau Tebyg

• Rosuvastatin reduces vascular inflammation and T cell and monocyte activation in HIV-infected subjects on antiretroviral therapy
  gan: Funderburg, Nicholas T., et al.
  Cyhoeddwyd: (2015)
• Rosuvastatin Preserves Renal Function and Lowers Cystatin C in HIV-Infected Subjects on Antiretroviral Therapy: The SATURN-HIV Trial
  gan: Longenecker, Chris T., et al.
  Cyhoeddwyd: (2014)
• Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy
  gan: Erlandson, Kristine M., et al.
  Cyhoeddwyd: (2015)
• Markers of inflammation and CD8+ T-cell activation, but not monocyte activation are associated with subclinical carotid artery disease in HIV
  gan: Longenecker, Chris T., et al.
  Cyhoeddwyd: (2013)
• Rosuvastatin Decreases Intestinal Fatty Acid Binding Protein (I-FABP), but Does Not Alter Zonulin or Lipopolysaccharide Binding Protein (LBP) Levels, in HIV-Infected Subjects on Antiretroviral Therapy
  gan: Funderburg, Nicholas T., et al.
  Cyhoeddwyd: (2016)